BioCentury | Oct 15, 2020
Finance

Oct. 14 Quick Takes: FDA approves first Ebola therapy; plus Vertex tumbles after hours on AAT discontinuation

...adsorbed onto the adjuvant aluminum hydroxide.Phase III misses for Otsuka’s guadecitabineOtsuka Pharmaceutical Co. Ltd. said guadecitabine...
...its approval of Makena hydroxyprogesterone to prevent premature births.TargetsIL-36R (ILRL2) - Interleukin-1 receptor-like 2 BC Staff VX-814 VX-864 Guadecitabine (SGI-110, s110) Makena...
BioCentury | Aug 3, 2018
Clinical News

Otsuka's guadecitabine misses in Phase III for first-line AML

...Ltd. (Tokyo, Japan) and its Astex Pharmaceuticals Inc. subsidiary said first-line treatment with guadecitabine (formerly SGI-110...
...in cash (see "Consolation Prize" ). Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Product: Guadecitabine (formerly SGI-110...
...response and safety Status: Phase III data Milestone: Phase III data (mid-2020) Jaime De Leon Guadecitabine (SGI-110, s110) Astex...
BioCentury | Jul 31, 2018
Clinical News

Otsuka's guadecitabine misses in Phase III for first-line AML

...Ltd. (Tokyo, Japan) and its Astex Pharmaceuticals Inc. subsidiary said first-line treatment with guadecitabine (formerly SGI-110...
...ASTRAL-1 trial to treat previously untreated acute myelogenous leukemia. The companies plan to continue evaluating guadecitabine...
...Astex in 2013 for $866 million in cash (see "Consolation Prize" ). Jaime De Leon Guadecitabine (SGI-110, s110) Astex...
BioCentury | Dec 9, 2017
Product Development

Multimodal meeting

...guadecitabine (SGI-110), in development at Otsuka Pharmaceutical Co. Ltd. to treat AML and other cancers. Guadecitabine...
...Tokyo:4523) Tazemetostat (EPZ-6438) EZH2 DLBCL, FL Phase II 2745, 4013 Otsuka Pharmaceutical Co. Ltd. Guadecitabine (SGI-110...
BioCentury | Oct 3, 2017
Distillery Therapeutics

Cancer

...leukemia (AML) and in Phase I testing to treat ovarian cancer. Otsuka also has guadecitabine (SGI-110...
BioCentury | Aug 22, 2016
Clinical News

Guadecitabine: Phase I/II started

...Cancer Research UK began the double-blind, placebo-controlled, U.K. Phase I/II SPIRE trial to evaluate subcutaneous guadecitabine...
...Pharmaceuticals Inc. subsidiary plus cisplatin and gemcitabine. The first part will test escalating doses of guadecitabine...
...remission chemotherapy. Otsuka Pharmaceutical Co. Ltd. , Tokyo, Japan Product: Guadecitabine ( SGI-110 ) (formerly S110...
BioCentury | Jun 23, 2016
Distillery Therapeutics

Therapeutics: DNA (cytosine-5-)-methyltransferase 1 (DNMT1)

...leukemia (AML) and in Phase I testing to treat ovarian cancer. Otsuka has guadecitabine ( SGI-110...
BioCentury | Apr 25, 2016
Company News

Genentech, Otsuka Pharmaceutical, Roche deal

...evaluate Astex’s guadecitabine ( SGI-110 ) and Genentech’s atezolizumab to treat acute myelogenous leukemia (AML). Guadecitabine...
BioCentury | Apr 14, 2016
Distillery Therapeutics

Therapeutics: Histone deacetylase (HDAC); DNA (cytosine-5-)-methyltransferase 1 (DNMT1)

...Phase I testing to treat B cell lymphoma. Otsuka Pharmaceutical Co. Ltd. has guadecitabine ( SGI-110...
BioCentury | Jul 16, 2015
Distillery Therapeutics

Therapeutics: DNA (cytosine-5-)-methyltransferase 1 (DNMT1)

...DNMT1 regulates obesity-associated metabolic complications. Otsuka Pharmaceutical Co. Ltd. has the small molecule DNMT1 inhibitor SGI-110...
Items per page:
1 - 10 of 32